Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C6H5O7.3Ca.4H2O |
Molecular Weight | 570.495 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=LNIZKKFWMDARJV-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Ca.4H2O/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;4*1H2/q;;3*+2;;;;/p-6
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
Title | Date | PubMed |
---|---|---|
Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. | 2000 Nov |
|
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D. | 2001 Jun |
|
Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
A diacylglycerol-activated Ca2+ channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP-6 (transient receptor potential) protein. | 2001 Sep 15 |
|
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:23:03 GMT 2023
by
admin
on
Fri Dec 15 17:23:03 GMT 2023
|
Record UNII |
MLM29U2X85
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 184.1195
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-VATC |
QA12AA09
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-ATC |
A12AA09
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-ATC |
A12AA13
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
||
|
WHO-VATC |
QA12AA13
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11093
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
SUB16376MIG
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
5282392
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
D019355
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106123
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
C1355
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
m2933
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000087584
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
SUB13170MIG
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
5785-44-4
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
4479
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
CALCIUM CITRATE
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
MLM29U2X85
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
47613
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
MLM29U2X85
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
1086414
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY | |||
|
DTXSID40893034
Created by
admin on Fri Dec 15 17:23:03 GMT 2023 , Edited by admin on Fri Dec 15 17:23:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |